See more : Mobility One Ltd. (JE00B1Z48326.SG) Income Statement Analysis – Financial Results
Complete financial analysis of Creative Medical Technology Holdings, Inc. (CELZ) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Creative Medical Technology Holdings, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Winc, Inc. (WBEV) Income Statement Analysis – Financial Results
- Ecofibre Limited (EOFBF) Income Statement Analysis – Financial Results
- Forum Merger IV Corporation (FMIV) Income Statement Analysis – Financial Results
- IGB Real Estate Investment Trust (5227.KL) Income Statement Analysis – Financial Results
- Modern Shares & Stockbrokers Limited (MODRNSH.BO) Income Statement Analysis – Financial Results
Creative Medical Technology Holdings, Inc. (CELZ)
About Creative Medical Technology Holdings, Inc.
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company offers CaverStem to treat erectile dysfunction; FemCelz for the treatment of loss of genital sensitivity and dryness; StemSpine to treat chronic lower back pain; ImmCelz for the treatment of stroke patients; and OvaStem for treatment of female infertility. Creative Medical Technology Holdings, Inc. is based in Phoenix, Arizona.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 9.00K | 88.60K | 87.75K | 164.50K | 165.50K | 124.40K | 4.80K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 3.60K | 28.49K | 47.95K | 50.60K | 45.50K | 70.38K | 8.00K | 766.07K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 5.40K | 60.11K | 39.81K | 113.90K | 120.00K | 54.03K | -3.20K | -766.07K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 60.00% | 67.84% | 45.36% | 69.24% | 72.51% | 43.43% | -66.67% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 1.97M | 6.27M | 109.18K | 0.00 | 0.00 | 96.62K | 260.09K | 85.33K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 1.22M | 1.05M | 898.53K | 664.98K | 20.83K | 19.43K | 20.12K | 20.10K | 0.00 | 14.29K | 30.55K | 53.49K | 13.62K | 1.43K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 3.56M | 3.94M | 2.96M | 1.16M | 1.22M | 1.05M | 898.53K | 664.98K | 20.83K | 19.43K | 20.12K | 20.10K | 19.83K | 14.29K | 30.55K | 53.49K | 13.62K | 1.43K |
| Other Expenses | 94.58K | 92.08K | 92.08K | 66.79K | 26.95K | 21.14K | 0.00 | 9.36K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 5.53M | 10.30M | 3.17M | 1.23M | 1.25M | 1.17M | 1.17M | 759.67K | 20.83K | 19.43K | 20.12K | 20.10K | 19.83K | 14.29K | 30.55K | 53.49K | 13.62K | 1.43K |
| Cost & Expenses | 5.63M | 10.33M | 3.21M | 1.28M | 1.30M | 1.24M | 1.18M | 759.67K | 20.83K | 19.43K | 20.12K | 20.10K | 19.83K | 14.29K | 30.55K | 53.49K | 13.62K | 1.43K |
| Interest Income | 333.56K | 100.33K | 4.28M | 1.23M | 1.90M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 469.00 | 2.33K | 1.95K |
| Interest Expense | 0.00 | 0.00 | 4.28M | 1.23M | 1.90M | 1.36M | 377.59K | 6.40K | 9.93K | 8.59K | 7.16K | 5.49K | 4.23K | 2.97K | 1.06K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 94.58K | 92.08K | 92.08K | 66.79K | 26.95K | 21.14K | 15.99K | 9.36K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -5.53M | -10.15M | -3.03M | -1.05M | -1.10M | -1.09M | -1.16M | -750.32K | -20.83K | -19.43K | -20.12K | -20.10K | -19.83K | -14.29K | -30.55K | -53.49K | -13.62K | -1.43K |
| EBITDA Ratio | -61,394.98% | -11,345.33% | -3,457.24% | -637.11% | -666.60% | -878.68% | -24,204.40% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -5.62M | -10.24M | -3.13M | -1.11M | -1.13M | -1.11M | -1.18M | -766.07K | -20.83K | -19.43K | -20.12K | -20.10K | -19.83K | -14.29K | -30.55K | -53.49K | -13.62K | -1.43K |
| Operating Income Ratio | -62,445.91% | -11,562.50% | -3,562.17% | -677.71% | -682.88% | -895.68% | -24,537.63% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 333.56K | 100.33K | 22.34M | -35.21M | -7.35M | -12.54M | -1.48M | -6.40K | -9.93K | -8.59K | -7.16K | -5.49K | -4.23K | -2.97K | -1.06K | 2.22K | 2.33K | 1.95K |
| Income Before Tax | -5.29M | -10.14M | 19.21M | -36.33M | -8.48M | -13.66M | -2.66M | -766.07K | -30.76K | -28.01K | -27.28K | -25.59K | -24.06K | -17.26K | -31.61K | -51.27K | -11.29K | 523.00 |
| Income Before Tax Ratio | -58,739.71% | -11,449.26% | 21,892.75% | -22,082.21% | -5,126.09% | -10,977.21% | -55,398.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -100.33K | 4.28M | 1.23M | 1.90M | -11.18M | 377.59K | 12.80K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.36K | -661.00 | 162.00 |
| Net Income | -5.29M | -10.04M | 14.93M | -37.55M | -10.38M | -13.66M | -2.66M | -766.07K | -30.76K | -28.01K | -27.28K | -25.59K | -24.06K | -17.26K | -31.61K | -52.64K | -9.54K | 1.37K |
| Net Income Ratio | -58,739.71% | -11,336.02% | 17,017.27% | -22,829.68% | -6,271.42% | -10,977.21% | -55,398.08% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.76 | -9.19 | 57.32 | -648.10 | -5.02K | -11.35K | -17.38K | -5.47K | -1.28K | -1.17K | -1.14K | -1.07K | -1.00K | -719.00 | -1.32K | -2.19K | -397.67 | 57.17 |
| EPS Diluted | -3.76 | -9.19 | 45.97 | -648.10 | -5.02K | -11.35K | -17.38K | -5.47K | -1.28K | -1.17K | -1.14K | -1.07K | -1.00K | -719.00 | -1.32K | -2.19K | -397.67 | 57.17 |
| Weighted Avg Shares Out | 1.41M | 1.09M | 260.51K | 57.95K | 2.07K | 1.20K | 153.00 | 140.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 |
| Weighted Avg Shares Out (Dil) | 1.41M | 1.09M | 324.86K | 57.95K | 2.07K | 1.20K | 153.00 | 140.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 | 24.00 |
Creative Medical Technology Holdings, Inc. Advances FDA Cleared ADAPT Clinical Trial with Positive Independent Review, Validating the Safety and Potential of CELZ-201 for Chronic Lower Back Pain Treatment
PHOENIX, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a biotechnology leader in regenerative medicine, is pleased to announce the successful completion of an independent interim safety review by the Data Safety Monitoring Board (DSMB)...
Creative Medical Technology Holdings Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program
PHOENIX, July 24, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial-stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that it...
Creative Medical Technology Holdings Provides Corporate Update
PHOENIX, July 10, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today provided a corporate update...
Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin
PHOENIX, June 24, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that...
Creative Medical Technology Holdings Provides Corporate Update
PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc., (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a biotechnology company focused on a regenerative approach to immunotherapy, endocrinology, urology, gynecology, and orthopedics, today provided a corporate update in connection with the filing of...
Creative Medical (CELZ) Up on Orphan Drug Tag for CELZ-101
Creative Medical's (CELZ) CELZ-101 gets FDA's Orphan Drug designation for preventing allograft rejection in type-I diabetes patients undergoing pancreatic islet cell transplantation. Stock rises.
Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access
PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc., (NASDAQ:CELZ), a leader in biotech innovation, today announced a major stride in combating Type 1 Diabetes Mellitus (T1D). The company has secured FDA authorization for an expanded access therapy using CELZ-201, a pioneering cell-based...
Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy
PHOENIX--(BUSINESS WIRE)--Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a leader in the field of regenerative medicine with a focus on developing novel therapies in immunotherapy, endocrinology, urology, gynecology, and orthopedics, is pleased to announce the successful receipt of Orphan Drug...
Creative Medical Technology Granted FDA Clearance for Chronic Back Pain Clinical Trial
New York, December 21, 2023 – Creative Medical Technology Holdings, Inc. (Nasdaq: CELZ) has received FDA clearance to conduct a phase 1/2 clinical trial using the company's innovative StemSpine® treatment known as AlloStem™ (CELZ-201-DDT).
Creative Medical Technology Holdings (NASDAQ:CELZ) Granted FDA Clearance To Begin Phase 1/2 Clinical Trial Of AlloStem(TM) For Addressing Chronic Lower Back Pain
PHOENIX, AZ / ACCESSWIRE / December 20, 2023 / Creative Medical Technology Holdings, Inc. (NASDAQ:CELZ), a biotechnology company has received clearance from the FDA to conduct a phase 1/2 clinical trial using their innovative StemSpine® treatment known as AlloStem™. This...
Source: https://incomestatements.info
Category: Stock Reports